The cytolytic
protein perforin has a crucial role in
infections and
tumor surveillance. Recently, it has also been associated with many
brain diseases, such as
neurodegenerative diseases and
stroke. Therefore, inhibitors of
perforin have attracted interest as novel drug candidates. We have previously reported that converting a
perforin inhibitor into an L-type
amino acid transporter 1 (LAT1)-utilizing
prodrug can improve the compound's brain drug delivery not only across the blood-brain barrier (BBB) but also into the brain parenchymal cells: neurons, astrocytes, and microglia. The present study evaluated whether the increased uptake into mouse primary cortical astrocytes and subsequently improvements in the cellular bioavailability of this brain-targeted
perforin inhibitor
prodrug could enhance its pharmacological effects, such as inhibition of production of
caspase-3/-7, lipid peroxidation products and
prostaglandin E2 (
PGE2) in the
lipopolysaccharide (LPS)-induced
neuroinflammation mouse model. It was demonstrated that increased brain and cellular drug delivery could improve the ability of
perforin inhibitors to elicit their pharmacological effects in the brain at nano- to picomolar levels. Furthermore, the
prodrug displayed multifunctional properties since it also inhibited the activity of several key
enzymes related to
Alzheimer's disease (AD), such as the β-site
amyloid precursor
protein (APP) cleaving
enzyme 1 (BACE1),
acetylcholinesterase (AChE), and most probably also
cyclooxygenases (COX) at micromolar concentrations. Therefore, this
prodrug is a potential drug candidate for preventing Aβ-accumulation and ACh-depletion in addition to combatting
neuroinflammation, oxidative stress, and neural apoptosis within the brain. Graphical abstract.